Last reviewed · How we verify
Zanosar (STREPTOZOCIN)
Streptozocin (Zanosar), marketed by Teva, is a chemotherapy agent indicated for the treatment of pancreatic neuroendocrine tumors. Its key strength lies in its unique mechanism of action, which disrupts DNA replication in cancer cells, setting it apart from other alkylating agents in its class. The primary risk is the competition from off-patent generics such as carmustine and lomustine, which may erode market share despite Zanosar's key composition patent expiring in 2028.
At a glance
| Generic name | STREPTOZOCIN |
|---|---|
| Sponsor | Teva |
| Drug class | Alkylating Drug [EPC] |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
| First approval | 1982 |
Approved indications
- Pancreatic Neuroendocrine Tumor
Common side effects
Key clinical trials
- An Open-label Study to Assess Safety and Efficacy of SZC in Paediatric Patients With Hyperkalaemia (PHASE3)
- MGMT-NET: O6-methylguanine-DNA Methyltransferase (MGMT) Status in Neuroendocrine Tumors: Predictive Factor of Response to Alkylating Agents (NA)
- The Effect of Sitagliptin, Pioglitazone and Dapagliflozine on Myocardial Infarction in Diabetic Rats (PHASE4)
- Effect of Melatonin in Patients With Diabetic Peripheral Neuropathy (PHASE2)
- Sequentiality of Everolimus and STZ-5FU in Advanced Pancreatic Neuroendocrine Tumor (PHASE3)
- Two Chemotherapy Regimens Plus or Minus Bevacizumab (PHASE2)
- Reduce Incidence of Pre-Dialysis Hyperkalaemia With Sodium Zirconium Cyclosilicate in Chinese Subjects (PHASE3)
- Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |